MOLN
MOLECULAR PARTNERS AG
$3.76
+0.53%
$151.0M
No data for this timeframe.
Vol
Market Cap$151.0M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (80%)
Inst. Holders1 funds
Inst. Value$1.6K
Inst. Activity0 buys / 1 sells
SEC Reports2
Press Releases2
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. V8·CIK 0001745114·Prev Close $3.74
Recent Activity
May 12, 2026
SEC
Molecular Partners reported Q1 2026 results showing a net loss of CHF 13.1M, improved from a CHF 16.8M loss in Q1 2025,
6-K — Impact 5/10
Mar 30, 2026
SEC
Molecular Partners AG announced the nomination of Clare Fisher for election to its Board of Directors at the upcoming 20
6-K — Impact 3/10
Inst.
UBS Group AG — TRIM
5,339 shares ($19.8K)
Inst.
UBS Group AG — ADD
10,199 shares ($39.0K)
May 12, 2026
earnings
Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317
<p>ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- <strong>Ad h
May 1, 2026
Press
Molecular Partners announced publication of Phase 1 data for MP0317, a tumor-localized CD40 agonist, in Nature Cancer. T
Impact 4/10
Mar 12, 2026
Press
Molecular Partners reported its 2025 financial results and provided updates on its clinical pipeline, including the init
Impact 6/10
Price Targets
$11.08
+194.8% upside
Strong Buy
Current $3.76
Low $3.76
Median $11.93
High $16.90
5 analysts
$3.76
$16.90
Analyst Ratings
3Strong Buy
5Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 22, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Mar 16, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Jan 27, 2026 | HC Wainwright & Co. | INITIATE | Buy |
| Dec 8, 2025 | JP Morgan | MAINTAIN | Neutral → Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.34 ▼ -1.5% | $-0.34 — $-0.34 | 39% YoY | 1 |
| Next Q | $-0.34 | $-0.34 — $-0.34 | -3% YoY | 1 |
| Current FY | $-1.15 ▼ -3.0% | $-1.42 — $-0.65 | 30% YoY | 3 |
| Next FY | $-0.22 ▼ -10.2% | $-1.35 — $1.81 | 81% YoY | 3 |
Latest Reports
NEUTRAL
6-K
5/10
Molecular Partners reported Q1 2026 results showing a net loss of CHF 13.1M, improved from a CHF 16.8M loss in Q1 2025,
May 12, 2026
NEUTRAL
Press
4/10
Molecular Partners announced publication of Phase 1 data for MP0317, a tumor-localized CD40 agonist, in Nature Cancer. T
May 1, 2026
NEUTRAL
6-K
3/10
Molecular Partners AG announced the nomination of Clare Fisher for election to its Board of Directors at the upcoming 20
Mar 30, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $1.6K | TRIM |
1 institutional holders with $1.6K total value (367 shares) as of 2025-Q4. Top holders: MORGAN.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 367 | $1.6K | 100.0% | TRIM -26.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| UBS Group AG | TRIM | 10,199 | 5,339 | -47.7% | $19.8K | 2025-Q3 |
| UBS Group AG | ADD | 6,351 | 10,199 | +60.6% | $39.0K | 2025-Q2 |
| UBS Group AG | ADD | 5,246 | 6,872 | +31.0% | $32.6K | 2024-Q4 |
| MORGAN STANLEY | TRIM | 500 | 367 | -26.6% | $1.7K | 2024-Q4 |
| MORGAN STANLEY | ADD | 367 | 500 | +36.2% | $2.5K | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
2 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 4.0/10.
Current analyst consensus: Strong Buy (80% buy). Based on 10 analysts: 3 strong buy, 5 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$11.08 mean target
+194.8% upside
Strong Buy (1.40)
$3.76 Low
$16.90 High
| Metric | Value |
|---|---|
| Current Price | $3.76 |
| Target Low | $3.76 |
| Target Mean | $11.08 |
| Target Median | $11.93 |
| Target High | $16.90 |
| # Analysts | 5 |
| Recommendation | Strong Buy (1.40) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.34 | $-0.34 | $-0.34 | 39.3% | -1.5% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.34 | $-0.34 | $-0.34 | -3.0% | +0.0% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-1.15 | $-1.42 | $-0.65 | 30.3% | -3.0% | 0↑ 1↓ | $0.0B | 0.0% | 3 |
| Next FY 2027-12-31 |
$-0.22 | $-1.35 | $1.81 | 81.2% | -10.2% | — | $0.0B | 450.0% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.340 | |
| 7d ago | $-0.335 | -0.005 |
| 30d ago | $-0.335 | -0.005 |
| 60d ago | $-0.320 | -0.020 |
| 90d ago | $-0.310 | -0.030 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 22, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 16, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 27, 2026 | HC Wainwright & Co. | INITIATE | — | Buy |
| Dec 8, 2025 | JP Morgan | MAINTAIN | Neutral | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 3 | 5 | 2 | 0 | 0 | 80% | |
| Apr 1, 2026 | 3 | 5 | 2 | 0 | 0 | 80% | |
| Mar 1, 2026 | 3 | 5 | 2 | 0 | 0 | 80% | |
| Feb 1, 2026 | 3 | 5 | 2 | 0 | 0 | 80% | |
| Jan 1, 2026 | 3 | 5 | 2 | 0 | 0 | 80% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 12, 2026
earnings
Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317
<p>ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- <strong>Ad hoc announcement pursuant to Art. 53 LR</strong> <a
May 4, 2026
other
Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences
<p>ZURICH-SCHLIEREN, Switzerland and Concord, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=kAdYzxV7NO
May 1, 2026
fda
Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling
<p>ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- <strong>Ad hoc announcement pursuant to Art. 53 LR</strong> <
Apr 19, 2026
routine
Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712
<p>ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass, April 19, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=fxjs0GtGz
Apr 14, 2026
other
Molecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General Meeting
<p align="left">ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- <strong>Ad hoc announcement pursuant to Art. 5
Mar 23, 2026
other
Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors
<p>ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 23, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=skmtj-Jd
Mar 19, 2026
other
Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins’ Amenability to Multiple Isotopes
<p align="left">ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?
Mar 17, 2026
routine
Molecular Partners to Hold Three Poster Presentations at AACR 2026
<p align="left">ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?
Mar 12, 2026
earnings
Molecular Partners Reports Highlights and Financial Results for Full Year 2025
<p>ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- <strong>Zurich-Schlieren, Switzerland and Concord, Mass., Ma